Dnca Finance Sells 39,000 Shares of Medtronic PLC $MDT

Key Points

• Dnca Finance trimmed its stake in Medtronic by 40.8%, selling 39,000 shares in Q3 and leaving 56,550 shares valued at about $5.39 million.
• EVP Harry Skip Kiil sold 52,524 shares on Feb. 19 for roughly $5.13 million, cutting his ownership by ~61.6%; insiders now hold 0.26% of the stock.
• Medtronic slightly beat quarterly estimates with $1.36 EPS and $9.02B revenue, set FY2026 guidance of $5.62–$5.66 EPS, and announced a $0.71 quarterly dividend (annualized $2.84, ~3.3% yield; ex-dividend Mar. 27).

Dnca Finance trimmed its position in Medtronic PLC (NYSE:MDT - Free Report) by 40.8% in the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 56,550 shares of the medical technology company's stock after selling 39,000 shares during the quarter. Dnca Finance's holdings in Medtronic were worth $5,386,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in MDT. Towarzystwo Funduszy Inwestycyjnych PZU SA lifted its position in Medtronic by 4.2% during the 3rd quarter. Towarzystwo Funduszy Inwestycyjnych PZU SA now owns 4,910 shares of the medical technology company's stock valued at $468,000 after purchasing an additional 200 shares during the period. Siemens Fonds Invest GmbH grew its position in shares of Medtronic by 5.8% during the 3rd quarter. Siemens Fonds Invest GmbH now owns 61,941 shares of the medical technology company's stock worth $5,899,000 after buying an additional 3,409 shares during the period. Wellington Management Group LLP grew its position in shares of Medtronic by 35.3% during the 3rd quarter. Wellington Management Group LLP now owns 10,189,586 shares of the medical technology company's stock worth $970,456,000 after buying an additional 2,658,981 shares during the period. Wayfinding Financial LLC bought a new stake in shares of Medtronic during the third quarter worth approximately $210,000. Finally, Diligent Investors LLC raised its stake in shares of Medtronic by 4.5% during the third quarter. Diligent Investors LLC now owns 9,998 shares of the medical technology company's stock worth $952,000 after buying an additional 432 shares during the last quarter. 82.06% of the stock is owned by institutional investors.

Insider Transactions at Medtronic

In other Medtronic news, EVP Harry Skip Kiil sold 52,524 shares of the business's stock in a transaction dated Thursday, February 19th. The stock was sold at an average price of $97.71, for a total value of $5,132,120.04. Following the completion of the transaction, the executive vice president directly owned 32,768 shares of the company's stock, valued at approximately $3,201,761.28. The trade was a 61.58% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders own 0.26% of the company's stock.

Medtronic Stock Down 0.4%

Shares of NYSE:MDT opened at $87.05 on Friday. The company has a 50 day moving average price of $97.96 and a two-hundred day moving average price of $96.84. The company has a debt-to-equity ratio of 0.57, a quick ratio of 1.87 and a current ratio of 2.54. The company has a market capitalization of $111.77 billion, a PE ratio of 24.25, a PEG ratio of 2.24 and a beta of 0.71. Medtronic PLC has a 52 week low of $79.55 and a 52 week high of $106.33.

Medtronic (NYSE:MDT - Get Free Report) last announced its quarterly earnings results on Tuesday, February 17th. The medical technology company reported $1.36 earnings per share for the quarter, topping analysts' consensus estimates of $1.34 by $0.02. Medtronic had a net margin of 13.00% and a return on equity of 14.82%. The company had revenue of $9.02 billion for the quarter, compared to analysts' expectations of $8.89 billion. During the same period last year, the firm posted $1.38 earnings per share. The business's quarterly revenue was up 5.8% compared to the same quarter last year. Medtronic has set its FY 2026 guidance at 5.620-5.660 EPS. Analysts forecast that Medtronic PLC will post 5.46 earnings per share for the current year.

Medtronic Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Friday, April 17th. Shareholders of record on Friday, March 27th will be issued a dividend of $0.71 per share. The ex-dividend date is Friday, March 27th. This represents a $2.84 annualized dividend and a yield of 3.3%. Medtronic's payout ratio is currently 79.11%.

Analysts Set New Price Targets

MDT has been the subject of a number of analyst reports. Wells Fargo & Company started coverage on shares of Medtronic in a report on Friday, January 30th. They set an "overweight" rating and a $114.00 target price for the company. The Goldman Sachs Group set a $111.00 price target on Medtronic and gave the company a "neutral" rating in a research note on Wednesday, November 19th. Robert W. Baird reduced their price target on Medtronic from $103.00 to $100.00 and set a "neutral" rating on the stock in a research report on Wednesday, February 18th. Citigroup began coverage on Medtronic in a research note on Tuesday, February 3rd. They set a "buy" rating and a $117.00 price objective for the company. Finally, TD Cowen reiterated a "buy" rating on shares of Medtronic in a report on Friday, November 14th. One equities research analyst has rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating and ten have issued a Hold rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and a consensus target price of $110.74.

About Medtronic

Medtronic plc is a global medical technology company that develops and manufactures a broad range of therapeutic devices and health care solutions. Headquartered legally in Ireland with principal operational offices in the United States, the company markets products to hospitals, physicians and health systems worldwide and has grown from its founding in 1949 into one of the largest medical-device manufacturers serving global health-care markets.

Medtronic's offerings span several clinical areas, including cardiac rhythm and heart failure (pacemakers, implantable cardioverter‑defibrillators and related cardiac therapies), minimally invasive and surgical technologies (laparoscopic and advanced energy devices, visualization systems and surgical innovations), restorative therapies (spine and orthopedics, neuromodulation and neurovascular treatments) and diabetes management (insulin-delivery systems and glucose monitoring solutions).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.